NewsRoom Articles - Page 113 of 207

FridayMar 11, 2022 12:49 pm

Decisive Actions the Biden Administration Plans to Take to Combat Addiction and the Overdose Crisis

The numbers of individuals succumbing to drug overdoses has increased significantly these last few years, which has left many communities and families devastated. Figures show that between September 2020 and September 2021, more than 104,000 individuals in America died due to drug overdoses. President Joseph Biden recently revealed the actions that his administration would take to address this epidemic caused by addiction, laying out a vision for how the administration would expand harm reduction, evidence-based prevention, supply reduction, recovery and treatment approaches in an attempt to save lives. These decisive actions include: Putting an end to illicit drug trafficking Cross-border…

FridayMar 11, 2022 10:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Reports Positive Pre-IND Meeting with FDA, Changes to Its Clinical Trial Approach; Plans Breakthrough Therapy Designation Request for MYCO-001

Mydecine recently reported a positive Pre-IND meeting with the FDA for the MYCO-001 smoking cessation study According to the Center for Disease Control (“CDC”), tobacco is the leading cause of preventable deaths in the U.S. Following the FDA meeting, the company now intends to perform a Phase 2b study and then a Phase 3 study instead of a seamless Phase 2/3 clinical trial Mydecine plans to submit a request for breakthrough therapy status with its IND submission Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) has continually taken steps toward fulfilling its mission to become a trusted source of safe and…

ThursdayMar 10, 2022 11:49 am

Studies Find That Digital Health Tech Is Effective in Combating Chronic Illnesses

A study coauthored by Stanford Healthcare and Included Health that was looking into the efficacy of digital tools in managing chronic ailments has found that telehealth services have had a net positive impact on patients with hypertension. While digital health may be relatively new, the coronavirus pandemic was a game-changer for the field. With millions of people in locked-down areas and hospitals filling with coronavirus patients, a lot of people could not receive in-person medical care. However, thanks to digital tools such as phone calls and video calls, people battling chronic ailments were still able to stay up-to-date with their treatments.…

WednesdayMar 09, 2022 12:54 pm

Researchers Discover Disordered Alcohol Use Leads to Poor Functional Brain Connectivity

A recently published study has found that modified neural activity patterns may compromise the ability of some individuals to interpret facial expressions. The researchers found that individuals predisposed to alcohol problems and heavy drinking may have altered signaling patterns in regions of the brain that process social situations and emotions. In their report, the researchers explained that differences in brain connectivity could help forecast future alcohol use for an individual as well as offer the basis for new interventions for the prevention and treatment of alcohol use disorder. The risk of developing alcohol use problems has been linked to a…

WednesdayMar 09, 2022 9:30 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Updates Recent Product Diversification Efforts and Strategic Acquisitions Developments; Announces VP Of Sales & Marketing Appointment

In a recent update, InMed Pharmaceuticals president and CEO, Eric A. Adams, lauded the company’s progress and achievements so far, particularly with its product diversification and strategic acquisitions Adams noted the company’s commitment to launching more products and executing more programs to continue growing its product portfolio InMed also announced the appointment of Gerald (“Jerry”) P. Griffin III as Vice President of Sales and Marketing at BayMedica, its wholly-owned subsidiary In a conference call and webcast on February 15, 2022, Eric A. Adams, President and Chief Executive Officer of InMed Pharmaceuticals (NASDAQ: INM), emphasized the company’s successful product diversification and…

TuesdayMar 08, 2022 3:25 pm

National Brain Tumor Society, Yale Collaborate to Form DNA Damage Response Consortium

The National Brain Tumor Society and Yale University have partnered to conduct research on response mechanisms for DNA damage in an attempt to find new treatments for brain tumor patients. The National Brain Tumor Society is the biggest not-for-profit organization focused on brain cancer in the United States. The initiative, called the DNA Damage Response Consortium, will be led by Professor Ranjit Bindra of the School of Medicine at Yale University. Bindra is the scientific director of the Chênevert Brain Tumor Center, in addition to being a professor of therapeutic radiology. In an interview, Bindra explained that the damage response…

MondayMar 07, 2022 12:40 pm

New Study Finds That Family Members of Patients with Severe COVID Infections May Suffer PTSD

A new study has found that family members of individuals who have been hospitalized in the ICU due to coronavirus infections may suffer from PTSD in comparison with family members of patients with acute respiratory distress syndrome caused by other ailments. The study, which was conducted by French researchers, reported its findings in “JAMA Network.” For their study, the researchers carried out a prospective cohort study in 23 intensive care units in France between January and June 2020, with a final follow-up being conducted that same year in October. Family members of individuals with and survivors of acute respiratory distress…

MondayMar 07, 2022 11:15 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Gives Corporate Presentation, Q&A Session at Virtual Investor 2022 Top Picks Conference

The company also participated in the H.C. Wainwright BioConnect Conference earlier in January CNS Pharmaceuticals recently received approval from swissethics for a pivotal Berubicin and GBM clinical trial The five-year survival rate for GBM is only 6.8%, with the average patient population surviving 12 to 18 months after diagnosis CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, recently participated in the Virtual Investor 2022 Top Picks Conference. During the event, CEO John Climaco provided a corporate presentation and then participated in a…

MondayMar 07, 2022 11:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Chopra Foundation Partner in Efforts to Support Progress Toward Psychedelic-Based Therapeutics

Psychedelic drugs are on cusp of entering mainstream treatment for mental illness Cybin, Chopra Foundation to collaborate on efforts aimed to support education, awareness about psychedelic therapy mental health research Cybin “one of the only companies that may truly address the needs of patients and providers,” says Dr. Deepak Chopra A significant increase in research and growing public support are key indicators of the future of psychedelics, which are “on the cusp of entering mainstream psychiatry,” according to a recent “New York Times” article (https://ibn.fm/GshwS). Another strong indicator of the future of psychedelics is the exciting partnership just announced by…

FridayMar 04, 2022 9:30 am

Study Finds That Walkable Neighborhoods Decrease Prevalence of Diabetes, Obesity

A new study has found that individuals living in neighborhoods having access to outdoor activities and parks have a reduced chance of suffering from obesity or diabetes because the neighborhood residents are more active. Data shows that more than 11% of the U.S. population has diabetes with almost one-half of adults also suffering from obesity. Gillian L. Booth, colead author of the study, stated that the built environment influenced the levels of physical activity an individual undertook, through the promotion of active forms of transportation, such as cycling and walking, over passive ones, such as driving a car. The built…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Decisive Actions the Biden Administration Plans to Take to Combat Addiction and the Overdose Crisis

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Reports Positive Pre-IND Meeting with FDA, Changes to Its Clinical Trial Approach; Plans Breakthrough Therapy Designation Request for MYCO-001

Studies Find That Digital Health Tech Is Effective in Combating Chronic Illnesses

Researchers Discover Disordered Alcohol Use Leads to Poor Functional Brain Connectivity

InMed Pharmaceuticals Inc. (NASDAQ: INM) Updates Recent Product Diversification Efforts and Strategic Acquisitions Developments; Announces VP Of Sales & Marketing Appointment

National Brain Tumor Society, Yale Collaborate to Form DNA Damage Response Consortium

New Study Finds That Family Members of Patients with Severe COVID Infections May Suffer PTSD

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Gives Corporate Presentation, Q&A Session at Virtual Investor 2022 Top Picks Conference

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Chopra Foundation Partner in Efforts to Support Progress Toward Psychedelic-Based Therapeutics

Study Finds That Walkable Neighborhoods Decrease Prevalence of Diabetes, Obesity

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search